Maxim lowered the firm’s price target on Lucid Diagnostics (LUCD) to $2 from $3 and keeps a Buy rating on the shares after its Q1 revenue missed estimates. The company is still awaiting Medicare local coverage determination but remains proactive in its commercialization efforts ahead of potential coverage, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
- Analyst Reiterates Buy on Lucid, Maintains $2.50 Price Target Ahead of Potential Medicare Catalyst
- Lucid Diagnostics Earnings Call Balances Progress, Pressure
- Lucid Diagnostics reports Q1 adjusted EPS (7c), consensus (6c)
- Buy Rating Reaffirmed on Lucid Diagnostics as Medicare Coverage Prospects Support Unchanged $3 Price Target
- Lucid Diagnostics Reports Q1 2026 Results and Outlook